Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSPIRE
NCT04505566Phase 1Completed
- Start
- Nov 2020
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ketorolac tromethamine in diabetic retinopathy (DR) (5 arms). Primary endpoints: PGE2 level during Diabetic Retinopathy progression at 1 year, Vascular Endothelial Growth Factor (VEGF) level during Diabetic Retinopathy progression at 1 year and 4 more. Started Nov 2020; status: completed.
02
Drugs
ketorolac tromethamine
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT04505566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04505566.